Related Experiment Video
Updated: May 16, 2026
Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy
Published on: August 9, 2024
Intensive therapy following upper limb botulinum toxin A injection in young children with unilateral cerebral palsy:
Brian Hoare1, Christine Imms, Elmer Villanueva
1Department of Occupational Therapy, La Trobe University, Bundoora, Australia.
Insights
Modified constraint-induced movement therapy (mCIMT) did not show superior results compared to bimanual occupational therapy (BOT) for children with unilateral cerebral palsy (CP) after botulinum toxin A (BoNT-A) injections. Both therapies improved upper limb function over time.
Area of Science:
- Pediatric Rehabilitation
- Neurology
- Occupational Therapy
Background:
- Botulinum toxin A (BoNT-A) injections are effective for improving upper limb function in children with unilateral cerebral palsy (CP).
- Identifying optimal post-injection therapies is crucial for maximizing functional gains and minimizing the burden on families.
- Modified constraint-induced movement therapy (mCIMT) and bimanual occupational therapy (BOT) are potential interventions following BoNT-A treatment.
Purpose of the Study:
- To compare the efficacy of mCIMT versus BOT in young children with unilateral CP after receiving BoNT-A injections.
- To determine if mCIMT offers superior functional improvements in the upper limb compared to BOT.
- To evaluate the impact of these therapies on overall upper extremity function and performance.
Main Methods:
- A randomized, controlled, evaluator-blinded trial involving 34 children (18 months to 6 years) with unilateral CP.
- Participants received either BoNT-A with mCIMT or BoNT-A with BOT for 8 weeks.
- Outcomes were assessed using the Assisting Hand Assessment, Quality of Upper Extremity Skills Test, and Pediatric Evaluation of Disability Inventory at 3 and 6 months.
Main Results:
- No significant differences in upper limb functional improvement were observed between the BoNT-A + mCIMT group and the BoNT-A + BOT group immediately post-intervention.
- Both intervention groups demonstrated improvements in upper limb function over the 8-week treatment period.
- Follow-up assessments at 6 months did not reveal a superior effect of mCIMT over BOT.
Conclusions:
- In young children with unilateral CP, mCIMT does not provide superior functional outcomes compared to BOT when administered after BoNT-A injections.
- Both mCIMT and BOT are effective in improving upper limb function in this population.
- Further research may explore other therapeutic combinations or patient-specific factors influencing treatment response.
Aim:
Botulinum toxin A (BoNT-A) combined with occupational therapy is effective in improving upper limb outcomes in children with unilateral cerebral palsy (CP). It is now essential to identify the most effective therapies following BoNT-A. Given the added burden for children and families, the aim of this study was to explore whether modified constraint-induced movement therapy (mCIMT) leads to sufficiently superior gains compared with bimanual occupational therapy (BOT) in young children with unilateral CP following BoNT-A injections.
Method:
In this randomized, controlled, evaluator-blinded trial, 34 children (20 males, 14 females; mean age 3y, SD 1y 4mo, range 18mo-6y) with unilateral CP were randomized using concealed allocation to one of two 8-week interventions. The experimental group (n=17) received BoNT-A and mCIMT. The comparison group (n=17) received BoNT-A and BOT. Participants were recruited from a physical rehabilitation clinic and randomized between August 2003 and May 2009. Primary outcome was measured using the Assisting Hand Assessment at 3 months. Secondary outcomes were measured at 3 months and 6 months using the Quality of Upper Extremity Skills Test, the Pediatric Evaluation of Disability Inventory, Canadian Occupational Performance Measure, and the Goal Attainment Scale.
Results:
There were no clinically important differences between groups at baseline. Immediately following intervention, there was no evidence of a superior effect for BoNT-A + mCIMT as determined by the Assisting Hand Assessment (estimated mean difference [EMD] 0.81, upper 95% confidence limit 3.6; p=0.32) or secondary outcomes. However, both groups showed improvement over time (BoNT-A + mCIMT: EMD 2.7, 95% confidence interval [CI] 0.7-5.2; BONT-A + BOT: EMD 4.7, 95% CI 2.1-8.6). Follow-up at 6 months also demonstrated no superior effect for BoNT-A + mCIMT.
Interpretation:
Following upper limb injection of BoNT-A, there was no evidence that mCIMT, despite the significantly increased intensity of the home programme, produced a superior effect across a range of outcomes compared with a structured programme of BOT in young children with unilateral CP.
